Since its emergence in 1978, canine parvovirus (CPV-2) has been a leading cause of morbidity and mortality in dogs. Treatment for parvovirus mainly consists of supportive care including fluid therapy, antibiotics, antiemetics, gastroprotectants, and analgesics. Recently, development of a monoclonal antibody (CPMA) that binds to CPV has provided a direct treatment for parvovirus infection. In a shelter setting, much as with private owners, finances are a limiting factor in being able to treat parvovirus. Length of treatment is the biggest factor contributing to cost of treatment, thus decreasing length of treatment may warrant a more expensive treatment such as CPMA to increase overall cost efficiency. Decreasing length of treatment would also decrease length of stay which is important in a shelter setting, as decreasing length of stay has positive impacts on behavior and health. The goal of this study was to look at the length of treatment, mortality rate, and cost of treatment between dogs treated with supportive care versus supportive care and CPMA in order to discover if the addition of CPMA to classic parvovirus treatment was worthwhile in a shelter setting from the stand point of length of treatment, cost, and mortality.